ACE2 and COVID-19: Therefore, the occurrence of specific comorbidities associated with RAS imbalance mediated by ACE2/ADAM17 along with specific genetic factors mainly associated with TMPRSS2 expression could be decisive for the clinical outcome of COVID-19.